Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

FDA Issues Warning on Domperidone

June 14, 2004 | A version of this story appeared in Volume 82, Issue 24

FDA is warning women not to use the unapproved drug domperidone to increase their milk production. According to several case studies, the drug caused arrhythmia, cardiac arrest, and sudden death in some patients receiving the intravenous form of the drug. It is approved only for gastric distress in some countries, but not for enhancing lactation. In the U.S., it has not been approved for any use. Women are purchasing the drug from compounding pharmacies and from foreign sources over the Internet, according to FDA. Domperidone, which is excreted in breast milk, is touted on several websites as safe and effective for milk production because the compound may increase the secretion of prolactin, a hormone that is needed for lactation. FDA also issued six warning letters to compounding pharmacies that sell domperidone and to firms that supply the drug for use in compounding.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.